TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06743581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Cemiplimab 350 mg administered intravenously on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Dupilumab 600 mg administered subcutaneously on day 1
Study: NCT05889416

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Audit and feedback through a quality registry
Description: Centres answer CR process and structure variables through the SWEDEHEART registry every six months for three years. Feedback will be accessible online and through annual reports, enabling comparisons with own prior and other centres´ results.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Audit and feedback through a quality registry
Description: Centres answer CR process and structure variables through the SWEDEHEART registry every six months for three years. Feedback will be accessible online and through annual reports, enabling comparisons with own prior and other centres´ results.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Implementation support
Description: On-site support to implement guidelines on secondary prevention applying practice facilitation - a multifaceted approach carried out by CR experts who enable personnel at intervention centres to address and overcome challenges in implementing guidelines.
Study: NCT06484621

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy-Based Physical Activity Intervention
Description: Provides experiential training in values-clarification and acceptance strategies to increase autonomous motivation for achieving self-determined physical activity goal via group-based workshops, email feedback, and brief support telephone calls.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity Education Control
Description: Provides didactic instruction on physical activity and behavioral strategies for achieving prescribed physical activity goals via group-based workshops, email feedback, and brief support telephone calls.
Study: NCT04956094

Intervention type: DIAGNOSTIC_TEST
Intervention: GGT/Uric Acid
Description: Standard laboratory blood testing for GGT and uric acid levels.
Study: NCT04679844

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MagnetOs Easypack Putty
Description: MagnetOs Easypack Putty used standalone in instrumented posterolateral fusion, 5cc-15c per spine level at the randomized assigned side.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Demineralized Bone Matrix or Fibers mixed with local autograft bone
Description: Demineralized Bone Matrix or Fibers (DBX or Grafton) mixed in a 1:1 vol% with local autologous bone graft used in instrumented posterolateral fusion, 5cc-15cc per level mixed with bone marrow aspirate/blood per spine level at the contralateral side.
Study: NCT06272461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine IV
Description: Intravenous Lidocaine Vs intravenous Ketamine in colorectal surgery for cancer

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine Injectable Solution
Description: Intravenous Lidocaine Vs intravenous Ketamine in colorectal surgery for cancer
Study: NCT03824106

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Participants randomized to the control arm will not receive any of the Frailty Management Interventions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Exercise
Description: A recent meta-analysis suggests 180 min/week of exercise (with a high challenge to balance) is most effective for fall prevention. Combined strength and endurance training performed at a moderate weekly frequency (i.e., two times per week) may promote marked gains on muscle hypertrophy, strength and power gains in frail older adults. Balance training is a key component of successful exercise programs for vulnerable older adults.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Exercise
Description: A recent meta-analysis suggests 180 min/week of exercise (with a high challenge to balance) is most effective for fall prevention. Combined strength and endurance training performed at a moderate weekly frequency (i.e., two times per week) may promote marked gains on muscle hypertrophy, strength and power gains in frail older adults. Balance training is a key component of successful exercise programs for vulnerable older adults.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Nutrition and Medication review
Description: Nutrition review: Conduct nutritional screening flow and review any questions, provide some additional counseling/coaching. Protein supplements will be provided to all participants unless contraindicated.~Medication review: Review/update current medication list and forward the list and medical history to the consultant study pharmacist.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein Supplement
Description: Protein supplementation will be provided.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: 1000 IU of oral vitamin D

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: 1000 IU of oral vitamin D

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: 1000 IU of oral vitamin D
Study: NCT06455085

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Augmented-Fracture Liaison Service Arm
Description: Patients are contacted by a patient navigator (serving as the liaison) and referred to a bone health clinician.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care Arm
Description: Patients will be mailed education materials and encouraged to follow up with their primary care physician.
Study: NCT04273555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]-FDG
Description: \[18F\]-FDG will be injected prior to PET/MRI imaging up to three times over the course of six months.
Study: NCT04885946

Intervention type: OTHER
Group type: OTHER
Intervention: Fecal microbiota transplantion (FMT)
Description: Single donor, fecal microbiota transplantion (FMT) from healthy human donors.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantion (FMT)
Description: Single donor, fecal microbiota transplantion (FMT) from healthy human donors.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Food coloring, water, glycerol
Study: NCT05218239

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Comparator: Routine education group
Description: Behavior guidance on pelvic floor muscle function training , including Knack method education , and Kegel exercise and other pelvic floor muscle training methods were taught to postpartum women.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Routine education group
Description: Behavior guidance on pelvic floor muscle function training , including Knack method education , and Kegel exercise and other pelvic floor muscle training methods were taught to postpartum women.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Global training group
Description: Global training was added on the basis of control group. The 30min-training plan is divided into 9 sections, of which, groups 1 to 8, each group takes about 3 minutes, the ninth group is cool down section, including stretching for 5 minutes and foam axis stretching for 1 minute.
Study: NCT06403670

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Group DP received 0.5 mcg/kg of dexmedetomidine IV for 30 seconds, then dexmedetomidine infusion was started at 0.1-0.7 mcg/kg/h. Propofol 1 mg/kg was administered after waiting for 5 minutes for adequate sedation to develop due to dexmedetomidine's delayed onset of action.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Group RP received remifentanil 0.1 mcg/kg intravenously for 30 seconds, then remifentanil infusion was started at 0.01-0.1 mcg/kg/min. After waiting 2 minutes to develop a sufficient sedation level, 1 mg/kg of propofol was given.
Study: NCT06422195

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic Needle Tip Positioning Technique in Short Axis Approach (DNTP - SA)
Description: Ultrasound guided radial artery cannulation by Dynamic Needle Tip Positioning Technique in Short Axis Approach (DNTP - SA) will be performed by an experienced anesthesiologist who has no subsequent role in the study. The ultrasound transducer is oriented transversely to the radial artery at the wrist, and the vessel appears as a circular anechoic structure in the ultrasound screen with gradual advancing of the needle till reaching the radial artery. Meanwhile, the ultrasound probe is being moved proximally in advance of the needle tip until it disappears from the ultrasound image. The cannula then advanced in the direction of the artery.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Long Axis Approach (LA)
Description: Ultrasound guided radial artery cannulation in Long Axis Approach (LA) will be performed by an experienced anesthesiologist who has no subsequent role in the study. In the LA-IP approach, an ultrasound probe is placed parallel to the radial artery and the artery appears as a tubular anechoic structure in ultrasound.
Study: NCT05272839

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hypoglycemic food group
Description: A booklet with 4 common food products, clinically validated against diabetes, with instructions for use will be presented to the diabetic patient. The selected food products have been assessed as anti-diabetic for humans through at least one fair randomized comparative clinical trial, with a follow-up of several weeks or months. While continuing to take his/her standard medication if any, the patient will be encouraged to follow his/her preferences within the established list of foods and spices: he is expected to choose 2 plants from the list and to consume each of them every day during the whole duration of the trial (12weeks).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: The control group will receive only lifestyle and dietary recommendations.
Study: NCT06048250

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mezigdomide
Description: Receive PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study: NCT04761822

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Moderna COVID-19 Vaccine
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Moderna COVID-19 Vaccine
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pfizer-BioNTech COVID-19 Vaccine
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pfizer-BioNTech COVID-19 Vaccine
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intramuscular injection
Study: NCT06324708

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: DXA
Description: Patients will undergo a femoral and lumbar DXA
Study: NCT05012761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SR419 capsules
Description: Ascending single and multiple doses of SR419 orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ascending single and multiple doses of placebo orally
Study: NCT05231668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR439459
Description: Powder for solution for infusion; IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for infusion; IV infusion
Study: NCT05647096

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NucleoCapture device
Description: 100ml NucleoCapture selective DNA adsorber
Study: NCT04765111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study: NCT05193825

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote Programming
Description: Patients in the experimental group (Group B) will have their internal pulse generators (IPGs) adjusted through a novel software that allows for remote DBS programming (NeurosphereTM Virtual Clinic)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Programming
Description: Patients in the active comparator group (Group A) will have their internal pulse generators (IPGs) adjusted through a standard procedure at their caregivers institution.
Study: NCT05956821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SIACI of cetuximab and bevacizumab
Description: Subjects will receive monthly dosing of bevacizumab (15 mg/kg) and cetuximab (200mg/m2)
Study: NCT05271162

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin 10 MG
Description: Empagliflozin 10 mg q.d; p.o

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1 tabl q.d; p.o
Study: NCT04774406

Intervention type: DRUG
Intervention: olaparib, rucaparib, niraparib, talazoparib, veliparib, pamiparib, fluzoparib
Description: All patients treated at least with 1 PARPi (alone or in combination)
Study: NCT06239974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vericiguat
Description: Patients will be prescribed vericiguat once a day for 6 months, starting at 2.5mg and titrated up to the full dose of 10mg per day (doubling of dose every 2 weeks) in addition to optimised medical therapy and standard follow-up like the control group

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Stress Cardiac Magnetic Resonance
Description: All patients will have stress CMR examinations at recruitment and at the end of trial.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Stress Cardiac Magnetic Resonance
Description: All patients will have stress CMR examinations at recruitment and at the end of trial.
Study: NCT06500949

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vagus Nerve Pulmonary Branch Block
Description: Following thoracotomy, the thoracic surgeon, under direct thoracoscopic guidance, used forceps to elevate the apex of the lung, thus exposing the main trunk of the pulmonary branches of the vagus nerve. The injection needle was then advanced from a lateral-to-medial direction, and 2.5 ml of 0.375% ropivacaine was administered in close proximity to the targeted vagal branch.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Vagus Nerve Pulmonary Branch Injection
Description: Following thoracotomy, the thoracic surgeon, under direct thoracoscopic guidance, used forceps to elevate the apex of the lung, thus exposing the main trunk of the pulmonary branches of the vagus nerve. The injection needle was then advanced from a lateral-to-medial direction, and 2.5 ml of normal saline was administered in close proximity to the targeted vagal branch.
Study: NCT05338983

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical anesthetic
Description: 20% Benzocaine gel will be applied on the area of infiltration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical anesthetic
Description: 20% Benzocaine gel will be applied on the area of infiltration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical anesthetic
Description: 20% Benzocaine gel will be applied on the area of infiltration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical anesthetic
Description: 20% Benzocaine gel will be applied on the area of infiltration

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Avent baby bottle warmer
Description: Warming device

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate
Description: 0.1ml of 8.4% of sodium bicarbonate will be removed from the 50ml vial by one ml insulin syringe , directly injected into the local anesthetic cartridge and will be shacked 5 times to mix the solution.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Buzzy device
Description: Bee-shaped apparatus consisting of two parts: the main vibrating body of a bee and detachable ice wings.~External application of Buzzy device during administration of dental anesthetic.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mepivacaine Hydrochloride
Description: Mepivacaine HCL 2% with Epinephrine 1:100,000 Local Anesthetic. Local Dental anesthetic infiltration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepivacaine Hydrochloride
Description: Mepivacaine HCL 2% with Epinephrine 1:100,000 Local Anesthetic. Local Dental anesthetic infiltration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepivacaine Hydrochloride
Description: Mepivacaine HCL 2% with Epinephrine 1:100,000 Local Anesthetic. Local Dental anesthetic infiltration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepivacaine Hydrochloride
Description: Mepivacaine HCL 2% with Epinephrine 1:100,000 Local Anesthetic. Local Dental anesthetic infiltration
Study: NCT05310721

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early time-restricted eating
Description: Participants will eat ad libitum within an 8-hour early eating window starting not later than 10am. No calorie-containing food or beverage intake will be allowed outside the 8-hour eating window. Participants will also receive standard recommendations on healthy lifestyle based on Mediterranean dietary pattern and physical activity recommendations for weight loss and health promotion

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Late time-restricted eating
Description: Participants will eat ad libitum within an 8-hour late eating window starting not earlier than 1pm. No calorie-containing food or beverage intake will be allowed outside the 8-hour eating window. Participants will also receive standard recommendations on healthy lifestyle based on Mediterranean dietary pattern and physical activity recommendations for weight loss and health promotion

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-selected time-restricted eating
Description: Participants will self-selected an 8-hour eating window to eat ad libitum. No calorie-containing food or beverage intake will be allowed outside the 8-hour eating window. Participants will also receive standard recommendations on healthy lifestyle based on Mediterranean dietary pattern and physical activity recommendations for weight loss and health promotion
Study: NCT04633343

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Small volume breath and fast breathing rate for 5 minutes
Description: Small volume breath and fast breathing rate delivered via mechanical ventilator.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Large volume breath and slow breathing rate for 5 minutes
Description: Large volume breath and slow breathing rate delivered via mechanical ventilator.
Study: NCT05406934

Intervention type: BIOLOGICAL
Intervention: Infliximab
Description: obseravation with investigation

Intervention type: BIOLOGICAL
Intervention: Infliximab
Description: obseravation with investigation

Intervention type: BIOLOGICAL
Intervention: Infliximab
Description: obseravation with investigation
Study: NCT05205447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3410738
Description: Oral LY3410738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3410738
Description: Oral LY3410738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3410738
Description: Oral LY3410738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3410738
Description: Oral LY3410738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Oral Itraconazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Description: Oral Carbamazepine
Study: NCT05537090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BV100
Description: Rifabutin for Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Syrup for oral administration
Study: NCT05661526

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bloodpoly board game
Description: Blood transfusion training given by Bloodpoly board game

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Text-to-speech group
Description: Blood transfusion training given by text-to-speech
Study: NCT06450184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimavanserin 34 mg
Description: 1 capsule of Pimavanserin Capsule 34mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NUPLAZID 34 MG Oral Capsule
Description: 1 capsule of Pimavanserin Capsule 34mg
Study: NCT03935997

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strengthening a Palliative Approach in Long-Term Care (SPA-LTC) Program
Description: Our team will work with long-term care homes in the study to implement the Strengthening a Palliative Approach in Long Term Care (SPA-LTC) which consists of the following core, evidence-informed components:~Palliative Champion Teams (to provide leadership and support implementation); Palliative Care Education (including illness trajectory pamphlets); Comfort Care Rounds with staff (for capacity building and reflection); Prognostic Tools to trigger end-of-life discussions; Palliative Care Conferences with families and residents; Bereavement Pamphlets; and Post-Bereavement Follow-Up for families, and staff.
Study: NCT05119933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YL-15293
Description: After a screening period of approximately 28 days, eligible patients will receive oral YL-15293 once daily until documented disease progression, unacceptable AEs, intercurrent illness prevents further administrations of study treatment, investigator's decision to withdraw the patient, the patient withdraws consent, pregnancy of the patient, or for administrative reasons (see Section 7.1). Following the end of treatment, patients will continue to be followed for safety for 30 days. Patients who permanently discontinue study treatment for reasons other than disease progression will have post-treatment follow-up for disease assessment until start of new anticancer treatment, patient withdraws consent, is lost to follow-up, death, or until the Sponsor stops the study, whichever comes first.